Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. Therapeutic alternatives: protionamide |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. Therapeutic alternatives: protionamide |
| Bolivia | LINAME 2011 - 2013 | No observations |
| Peru | 6.2.4 Anti-Tuberculosis | No observations |
| Chile | Essential and Prioritized Medications | No observations |
| Cuba | 6.2.10 Antituberculosos y antileprosos | No observations |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |
| List | Section | Observation |
|---|---|---|
| Ecuador | Essential Medicines List - Ecuador | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
This medicine requires a children care specialist. Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. Therapeutic alternatives: protionamide |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |